ArticleOncology letters2026
Silencing of small nuclear ribonucleoprotein polypeptide B inhibits the progression of esophageal squamous cell carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis. Small nuclear ribonucleoprotein polypeptide B (SNRPB) has been implicated in the progression of various types of cancer; however, the specific role of this protein in ESCC remains unclear. The present study aimed to investigate the expression and functional significance of SNRPB in ESCC. Bioinformatics analysis was performed to assess SNRPB expression and its clinical relevance in ESCC. Immunohistochemical staining of ESCC tissue samples demonstrated significantly elevated SNRPB expression in tumor tissues, compared with adjacent non-cancerous esophageal tissues. Analysis of public database (TCGA) and institutional clinical data revealed that high SNRPB expression was associated with poor prognosis and advanced clinical stage (T stage), respectively. To evaluate the functional role of SNRPB, a lentivirus-based short hairpin RNA vector was used to inhibit endogenous SNRPB expression in ESCC cell lines. Functional assays, including colony formation, flow cytometry and western blot analysis, demonstrated that SNRPB knockdown significantly inhibited cell proliferation, induced cell cycle arrest and promoted apoptosis. Moreover, molecular analysis indicated that SNRPB knockdown led to modulation of the cell cycle and proteins associated with apoptosis. These findings suggested that SNRPB is a key regulator of ESCC progression, through impacting cell proliferation and apoptosis. Collectively, results of the present study demonstrated that SNRPB may act as a potential prognostic biomarker and therapeutic target for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.